Definium Therapeutics, Inc.
DFTXUnited States
20 filed reports · 295 financial concepts · 2 earnings calls · 0 media appearances
Filed reports
20 reports · Dec 2021 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 14 | 1,813 | Mar 2022 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 5 | 1,491 | Dec 2021 to Dec 2025 |
| Current · 8-KSEC EDGAR | 1 | 1 | Mar 2026 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 6, 2026 | 265 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 7, 2026 | 176 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | May 7, 2026 | 1 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 26, 2026 | 497 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 6, 2025 | 216 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Jul 31, 2025 | 120 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 8, 2025 | 125 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Mar 6, 2025 | 319 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 7, 2024 | 101 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 13, 2024 | 91 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 8, 2024 | 89 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Feb 28, 2024 | 262 | Open |
Financial data
295 concepts · 3,305 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial294 concepts · 3,299 facts · Dec 2019 to Jul 2026
- Cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations31 · Dec 2019 to Jun 2026
- Stockholders equity (US GAAP)31 · Dec 2019 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value28 · Dec 2020 to Jun 2026
- Allocated share based compensation expense28 · Dec 2020 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect28 · Dec 2020 to Jun 2026
- Comprehensive income net of tax28 · Dec 2020 to Jun 2026
- Foreign currency transaction gain loss before tax28 · Dec 2020 to Jun 2026
- General and administrative expense (US GAAP)28 · Dec 2020 to Jun 2026
- Increase decrease in accounts payable28 · Dec 2020 to Jun 2026
- Increase decrease in accrued liabilities28 · Dec 2020 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets28 · Dec 2020 to Jun 2026
- Net cash provided by used in financing activities28 · Dec 2020 to Jun 2026
- Net cash provided by used in operating activities28 · Dec 2020 to Jun 2026
- Net income loss28 · Dec 2020 to Jun 2026
- Operating expenses (US GAAP)28 · Dec 2020 to Jun 2026
- Operating income loss28 · Dec 2020 to Jun 2026
- Other comprehensive income loss foreign currency transaction and translation adjustment net of tax28 · Dec 2020 to Jun 2026
- Other nonoperating income expense28 · Dec 2020 to Jun 2026
- Profit loss28 · Dec 2020 to Jun 2026
- Research and development expense28 · Dec 2020 to Jun 2026
- Share based compensation arrangement by share based payment award options outstanding intrinsic value28 · Dec 2020 to Jun 2026
- Goodwill impairment loss27 · Mar 2021 to Jun 2026
- Share based compensation arrangement by share based payment award options outstanding weighted average exercise price27 · Dec 2020 to Jun 2026
- Accounts payable current26 · Dec 2020 to Jun 2026
KPI1 concepts · 6 facts · Dec 2025 to Jun 2026
- Clinical Trial Participants6 · Dec 2025 to Jun 2026
Segments
Figures broken down by business line, region, product or another axis the company reports on.
No segment breakdowns.
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
2 calls · Nov 2025 to Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 6, 2026
- FY2025 Q3Nov 6, 2025
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.